Pfizer and British American Tobacco Face Dividend Coverage Questions
Pfizer and British American Tobacco each yield slightly above 6%, but their recent dividend coverage differs. Pfizer’s payout used 89% of free cash flow in the year through June 2026 and exceeded cash generation in fiscal 2023 and 2025, while BAT’s payout ratio jumped to 91% in fiscal 2025 after several years near 50% to 55%. Pfizer also has lower leverage, with net debt at 2.0 times EBITDA compared with 2.9 times for BAT.
Pfizer and BAT both offer yields just above 6%, yet their cash coverage paths differ. Pfizer’s dividend consumed 89% of free cash flow in the year to June 2026, after exceeding free cash flow in fiscal 2023 and 2025. Its CEO has said the payout can be maintained even under stressed scenarios, with growth expected after patent losses fade.
BAT’s payout stayed near half of free cash flow from fiscal 2021 through 2024, then reached 91% in fiscal 2025. It eased to 78% in the year to June 2026, and management expects cash conversion above 95% for the full year. BAT’s net debt is 2.88 times EBITDA, versus Pfizer’s 1.97 times.
Income-seeking investors, including retirees and pension funds, may watch these payouts closely because a 6% yield can form a meaningful part of household or institutional income. If coverage remains tight, Pfizer and BAT could face pressure to balance dividends against debt reduction, research spending, or tobacco alternatives. That trade-off may affect employees, creditors, and customers over time, though Pfizer's CEO has committed to maintaining its dividend and BAT cites a progressive payout and buyback.